JAK1 and Dravet syndrome: Collectively, ISGs as a group are significantly downregulated upon tofacitinib treatment, but the effect is not uniform across all ISGs (Figure 6c), indicating that JAK1/3 inhibition does not reduce all IFN signaling elevated in DS, which could be explained by the fact that the IFN pathways also employ JAK2 for signal transduction56,57.